Mycoplasma Detection (Ph. Eur. 2.6.7)

Rapid, sensitive mycoplasma detection for cell therapies, biologics, and biomanufacturing workflows, fully aligned with GMP and European Pharmacopoeia requirements (EP 10.1 chapter 2.6.7 Mycoplasmas).

GMP-Compliant Mycoplasma Testing for Cell Therapy and Biologics

What is this service?

Mycoplasma testing is a critical quality control step for biologics, vaccines, viral vectors, and ATMPs. These small bacteria can contaminate cell cultures without visible signs. BaseClear provides sensitive detection using validated workflows aligned with European Pharmacopoeia chapter 2.6.7 and GMP requirements.

Who is it for?

GMP-compliant mycoplasma testing supports cell therapy and ATMP developers, biopharmaceutical companies, vaccine and viral vector manufacturers, CMOs, and translational research groups. It is commonly used for cell banks, production cell lines, raw materials, in-process samples, and final product release.

Methodology

BaseClear uses validated NAT technology to detect a broad range of mycoplasma species in mammalian cell cultures. The workflow combines PCR-based detection with positive, negative, and internal controls under GMP-aligned laboratory conditions. This enables rapid, sensitive, and reliable testing that meets pharmacopeial requirements.

What you receive

Clients receive a GMP-compliant report that can be directly used in regulatory documentation or quality systems.

How GMP-compliant mycoplasma
testing works

1

STEP 1

Project consultation

Our specialists review your project, sample type, and regulatory requirements to define the right testing strategy. Where needed, matrix validation is assessed to confirm reliable assay performance.

2

STEP 2

Sample matrix/sample submission

You submit sample matrixes or samples such as supernatants, following our specifications.

3

STEP 3

Matrix validation

Where needed, matrix suitability testing confirms that sample-specific inhibitors do not affect assay performance. Once suitability is established, samples are analyzed using a validated PCR-based method aligned with European Pharmacopoeia 2.6.7 and GxP requirements.

4

STEP 4

Regulatory-ready report

You receive a comprehensive analytical report suitable for quality documentation, regulatory submissions, and manufacturing release testing.

Talk to our Scientists

Schedule a free consultation with our experts to discuss your testing needs and regulatory 
requirements. We’ll help design a compliant testing workflow for your project.

Frequently Asked Questions

What is mycoplasma contamination?

Mycoplasma contamination is the presence of bacteria from the Mollicutes class that lack a cell wall and frequently infect mammalian cell cultures. Because they are extremely small and do not cause visible turbidity in culture media, contamination often goes undetected without specialized testing. Mycoplasma infections can alter cellular metabolism, affect experimental outcomes, and compromise the safety of biopharmaceutical products.

Mycoplasma testing for biologics and cell-based products is required under pharmacopeial standards including European Pharmacopoeia chapter 2.6.7, USP <63>, and related GMP guidelines. These regulations specify validated detection methods and performance criteria for ensuring the absence of mycoplasma contamination.

Mycoplasma testing is typically required for master cell banks, working cell banks, production cell lines, raw materials of biological origin, in-process samples, and final drug products. Testing may also be required during routine cell culture maintenance or before initiating manufacturing campaigns.

Molecular detection methods can identify mycoplasma DNA within a few hours once testing begins. Rapid PCR-based workflows significantly reduce detection time compared with traditional culture-based methods, while maintaining the sensitivity required for regulated environments.

Validated molecular assays are designed to detect a wide spectrum of mycoplasma species known to contaminate cell cultures, including common contaminants such as Mycoplasma hyorhinis, Mycoplasma orale, and Mycoplasma pneumoniae, Mycoplasma arginini, Mycoplasma Synoviae, Mycoplasma fermentans, Archoleplasma laidlawii and Spiroplasma citri. Broad detection coverage is essential for reliable quality control.

Mycoplasma testing is essential for advanced therapy medicinal products (ATMPs) because contamination can directly impact patient safety and product efficacy. Regulatory authorities therefore require validated testing of cell banks and production materials before clinical use. 

Ready to ensure your cultures are mycoplasma-free?

Schedule a free consultation with our experts to discuss your testing needs and regulatory requirements. We’ll help design a compliant testing workflow for your project.

Contact us